High-Concentration TSLP Antibody Composition With Improved Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing preparations of therapeutic proteins, particularly high-concentration monoclonal antibodies targeting TSLP, face challenges related to stability, which affects their efficacy and usability.
Innovation Solution
A pharmaceutical composition comprising a TSLP antibody or its antigen-binding fragment, formulated with specific CDR sequences and adjuvants such as buffers, stabilizers, and surfactants, achieving concentrations between 50-400 mg/mL, enhances stability and bioactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the concentration of TSLP antibody is increased to achieve high therapeutic efficacy, then the treatment effectiveness is improved, but the stability of the preparation deteriorates
Solution Approach 1:
The patent introduces adjuvants as intermediary substances to mediate between the high-concentration antibody and the stability requirement. These adjuvants act as protective intermediaries that prevent direct interactions causing instability, allowing the antibody to maintain high concentration while remaining stable in the preparation.
Solution Approach 2:
The patent optimizes multiple parameters including pH, ionic strength, and temperature to create optimal conditions for both high antibody concentration and stability. By carefully adjusting these physical and chemical parameters, the preparation achieves a balance where 50-400 mg/mL antibody concentrations can be maintained stably.
2Duration of action of moving object
If the concentration of TSLP antibody is increased to reduce dosage frequency, then the duration of action is improved, but the manufacturing precision required increases
Solution Approach 1:
The patent systematically optimizes formulation parameters such as buffer composition, pH, and adjuvant concentrations to enable precise control of high-concentration antibody preparations. This parameter optimization allows manufacturing at 50-400 mg/mL concentrations with adequate precision, achieving extended therapeutic duration without excessive manufacturing complexity.
Solution Approach 2:
The adjuvants in the patent serve multiple functions simultaneously: they stabilize the high-concentration antibody, maintain pH balance, prevent aggregation, and ensure manufacturability. This multi-functionality reduces the need for multiple separate components, thereby simplifying the overall manufacturing process while achieving extended therapeutic duration.
3Stability of the object's composition
If adjuvants are added to improve stability, then the stability is improved, but the device complexity increases
Solution Approach 1:
The adjuvants selected in the patent are designed to perform multiple functions simultaneously: pH buffering, ionic strength adjustment, and stability enhancement. This multi-functionality means that while additional components are added, the number of separate formulation steps and parameters to control is minimized, thereby limiting the increase in overall formulation complexity.
Solution Approach 2:
The patent combines multiple stabilizing functions into a single integrated adjuvant system rather than using separate components for each function. This merging approach maintains improved stability while avoiding the complexity that would arise from managing multiple independent formulation elements.
Data Source
AI summary
A monoclonal antibody preparation targeting thymic stromal lymphopoietin (TSLP). A pharmaceutical composition containing a TSLP antibody or an antigen-binding fragment thereof, comprising: 50-400 mg/mL of the TSLP antibody or the antigen-binding fragment thereof, and an adjuvant. A preparation and kit containing the pharmaceutical composition, and a use of the preparation and kit in treatment of allergic inflammation or autoimmune diseases.